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ABSTRACT
Background. NUT carcinoma is a rare aggressive disease
caused by BRD4/3-NUT fusion, and C-MYC upregulation plays
a key role in the pathogenesis. Here, we report on the clini-
copathological characteristics of Korean patients with NUT
carcinoma and the in vitro efficacy of MYC-targeting agents
against patient-derived NUT carcinoma cell lines.
Materials and Methods. Thirteen patients with NUT carci-
noma were evaluated for p53, C-MYC, epidermal growth fac-
tor receptor (EGFR), HER2, and programmed cell death ligand
1 (PD-L1) by immunohistochemistry. The half maximal inhibi-
tory concentration (IC50) values of NUT carcinoma cell lines
(SNU-2972-1, SNU-3178S, HCC2429, and Ty-82) were deter-
mined using MYC-targeting agents, including bromodomain
and extraterminal (BET) inhibitors (I-BET, OTX-015, AZD5153)
and histone deacetylase (HDAC) inhibitors (vorinostat, romi-
depsin, panobinostat, CUDC-907).
Results. Primary tumor sites included head and neck (n = 9)
and lung (n = 4). The patient age ranged from 8 to 73 years
with the male/female ratio of 1.2:1. Nine patients died at
3–23.6 months (median, 10.6) after diagnosis. Eight patients
had been misdiagnosed initially with other diseases. One
patient with metastatic NUT carcinoma who received mass
excision plus metastasectomy followed by chemoradiotherapy
was a long-term survivor (>27 months). Although expressions
of C-MYC (8/12, 73%) and p53 (12/12, 100%) were commonly
observed, EGFR, HER2, and PD-L1 expressions were observed
in 2 of 7 (29%), 2 of 8 (25%), and 1 of 12 (8.3%) patients,
respectively. BET and HDAC inhibitors showed variable but
limited in vitro efficacy. However, a dual HDAC/PI3K inhibitor,
CUDC-907, was most potent against NUT carcinoma cells,
with an IC50 of 5.5–9.0 pmol/L. Consistent with these find-
ings, kinome short interfering RNA screening showed a posi-
tive hit for PI3KCA in NUT carcinoma cells. Panobinostat (IC50,
0.4–1.3 nmol/L) and a bivalent BET inhibitor, AZD5153 (IC50,
3.7–8.2 nmol/L), also showed remarkable efficacies.
Conclusion. East Asian patients with NUT carcinoma showed
dismal survival outcomes like Western patients, and CUDC-
907 might be promising in NUT carcinoma treatment. The
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Implications for Practice: NUT carcinoma (NC) is a disease caused by BRD-NUT fusion leading to C-MYC upregulation. NC is
often misdiagnosed and very aggressive, requiring development of effective therapeutic strategy. This article presents the
clinicopathological features of the largest series of NCs in East Asians and preclinical sensitivities to MYC-targeting agents
in NC cell lines. Patients with NC had grave outcomes and poor response to treatment. Among MYC-targeting agents,
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including BET and HDAC inhibitors, CUDC-907 (a dual PI3K/HDAC inhibitor) was most effective against NC cells, followed by
panobinostat (an HDAC inhibitor) and AZD5153 (a bivalent BET inhibitor). CUDC-907 might be promising in NC treatment.
INTRODUCTION
NUT carcinoma is a rare but aggressive disease first described
in 1991 as thymic carcinoma in young adults harboring the
novel translocation t(15;19)(q15;p13) [1]. BRD4-NUT was
identified as a major fusion transcript involving NUT on
chromosome 15q14 and BRD4 on chromosome 19p13
[2]. Thereafter, several variants of rearrangement, includ-
ing BRD3-NUT, NSD3-NUT, and ZNF532-NUT, have been
reported [3–5]. Although NUT carcinoma was initially re-
ported in children and young adults, the age distribution
has been wide (0-78 years) [6, 7]. The predilection midline
sites of NUT carcinoma include the head and neck, the tho-
rax, the salivary gland, and other rare locations (testis,
bladder, and thyroid) [7, 8]. Histologically, NUT carcinoma
shows sheets or nests of undifferentiated tumor cells with
or without abrupt squamous differentiation [9]. Therefore,
NUT carcinoma is often misdiagnosed as undifferentiated car-
cinoma or poorly differentiated squamous cell carcinoma [9].
Standard treatment for NUT carcinoma has not been well
established. Although local approaches, including complete
resection of the tumor and initial radiotherapy, significantly
improved the survival of patients with NUT carcinoma [7, 8],
their use is not always possible because of locally advanced
or metastatic disease [7]. The clinical outcomes of chemother-
apy and radiotherapy were variable across several studies
[7, 8, 10]. Despite multimodal treatments, the survival out-
come is generally dismal (median overall survival, 4.7-9.7
months) [6–8, 10]. The pathophysiology of NUT carcinoma
depends on NUT translocation, which mostly transcribes
BRD4-NUT fusion protein binding to chromatin via the bromo-
domain, forming a transcriptionally active domain by recruiting
histone acetyltransferase (HAT) and transcription factors, acti-
vating certain oncogenes (e.g., C-MYC), and leading to dysre-
gulation of normal differentiation [5, 11–14]. Therefore, many
researchers have focused on targeted agents, including the
bromodomain and extraterminal (BET) and histone deacety-
lase (HDAC) inhibitors [12, 15]. Both inhibitor types were
demonstrated to abrogate dysregulated growth and induce
squamous differentiation of NUT carcinoma in vitro and in
vivo, which are translated into clinical activities [12, 16, 17].
In this study, we assessed clinicopathological features
and treatment outcomes of 13 patients diagnosed with
NUT carcinoma in multiple Korean centers. We also com-
pared the in vitro efficacy of MYC-targeting agents against
patient-derived NUT carcinoma cell lines.
MATERIALS AND METHODS
Patients
A total of 13 patients with NUT carcinoma from Seoul
National University Hospital, Severance Hospital, Gangnam
Severance Hospital, and Seoul Metropolitan Government-
Seoul National University Boramae Medical Center, Korea,
were included in this study (Table 1). Tissue samples from
one patient (NUT carcinoma [NC] 2) were obtained from the
Human Tissue Bank of Gangnam Severance Hospital, Yonsei
University College of Medicine (no. HTB-P2017-19). Four
cases (NC2–5) were reported previously [18–20]. Clinical
data, including tumor location, initial symptoms, stage, and
treatment outcomes, were obtained from medical records.
Response assessment was performed using RECIST 1.1 [21].
Progression-free survival (PFS) was calculated from the date
of initial treatment to the date of whichever came first
among progression, relapse, death, and last follow-up visit.
Overall survival (OS) was measured from the date of initial
diagnosis to the date of death or last follow-up visit, with a
cutoff in January 2018. Survival was analyzed with Kaplan-
Meier plots and the log-rank test using IBM SPSS statistics
24 software (IBM; Armonk, NY). TNM classification was
based on the 7th edition of the American Joint Committee
on Cancer’s cancer staging. The present study was approved
by the Institutional Review Board of Seoul National Univer-
sity Hospital (no. 1706-059-859).
Histological Examination and Immunohistochemistry
Experienced pathologists at each hospital reviewed the patho-
logical materials, including hematoxylin and eosin-stained and
NUT immunohistochemistry (IHC) slides. Two pathologists
(M.J., Y.K.J.) reviewed all pathological slides. IHC was per-
formed on formalin-fixed paraffin-embedded (FFPE) tissue
using the following antibodies: monoclonal rabbit antibodies
against NUT (clone C52B1; Cell Signaling Technology;
Danvers, MA): C-MYC (clone EP121 [also known as clone
Y69]; Cell Marque; Rocklin, CA), synaptophysin (clone Z66;
Invitrogen; Carlsbad, CA), HER2/neu (clone 4B5; Ventana,
Tucson, AZ), and programmed cell death ligand 1 (PD-L1;
clone E1L3N; Cell Signaling Technology); and monoclonal
mouse antibodies against p63 (clone A4A; Ventana): CD56
(clone 123C3; Invitrogen), chromogranin (clone 5H7; Leica
Biosystems; Wetzlar, Germany), p53 (clone DO-7; Dako;
Glostrup, Denmark), epidermal growth factor receptor (EGFR;
clone 3C6; Ventana), cytokeratin (clone AE1/AE3; Dako), CK5/6
(clone D5/16 B4; Dako), CK19 (clone RCK108; Dako), and CK20
(clone Ks 20.8; Dako). IHC was performed using the Bench-
Mark autostainer (Ventana) with appropriate control tissue on
every slide. NUT staining was interpreted as positive when
most (>50%) tumor cells showed distinct nuclear expression of
NUT [22].
Fluorescence In Situ Hybridization
Interphase fluorescence in situ hybridization (FISH) was per-
formed for every collected case on 3-μm-thick FFPE tissue
using the ZytoLight SPEC NUTM1 dual color break-apart
probe (PL166, ZytoVision; Bremerhaven, Germany) to detect
translocation involving the NUT gene according to the man-
ufacturer’s instructions. After counterstaining of the nuclei,
the slides were examined using Allegro Plus with a Solo
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Touch Workstation (BioView Ltd.; Rehovot, Israel) and
reviewed manually by pathologists (M.J., Y.K.J.) under an
Olympus BX51TRF microscope (Olympus Corporation; Tokyo,
Japan) equipped with the appropriate filters. NUT FISH results
were interpreted as positive as described previously [22].
Kinome Short Interfering RNA Screening
SNU-2972-1 and SNU-3178S cells that had been established
from patients with NC4 and NC5, respectively [18], were
seeded at a density of 10,000 cells per well (384-well
plates). Four different short interfering RNAs (siRNAs) tar-
geting human protein kinases (Dharmacon; Lafayette, CO)
were transfected into cells with final concentrations of
15 nM (3.75 nM each, pooled) using lipofectamine RNAi-
Max reagent (Life Technologies; Carlsbad, CA). Transfected
cells were incubated for 84 h, and the Cell Counting Kit-8
assay (Dojindo; Kumamoto, Japan) was performed accord-
ing to the manufacturer’s protocol.
Cell Culture, Reagents, and Cell Proliferation
SNU-2972-1 and SNU-3178S cell lines were obtained from the
Korean Cell Line Bank, and Ty-82 cells were purchased from the
JCRB Cell Bank. The HCC2429 cell line was provided byMatthew
Meyerson (Dana-Farber Cancer Institute; Boston, MA). SNU-
3178S cells harbored BRD3-NUT fusion and SNU-2972-1, Ty-82,
and HCC2429 cells had BRD4-NUT fusion [18]. All cells were
maintained in RPMI 1640medium supplementedwith 10% Fetal
bovine serum (Gibco by Life Technologies) and 1% penicillin-
streptomycin in a humid environment of 5% CO2 at 37
C.
CUDC-907, panobinostat, vorinostat, romidepsin, I-BET,
OTX-015, and AZD5153 were purchased from Selleckchem
(Houston, TX). Cells were seeded in 96-well plates at 1 × 104
with vehicle (0.1% dimethyl sulfoxide) or increasing concentra-
tions of drugs from 0.01 nmol/L to 10,000 nmol/L for 72 h. To
detect viability, the Cell Titer-glo reagent (Promega; Madison,
WI) was added according to the manufacturer’s instructions.
The plates were read using a luminescence microplate reader
(Promega). GraphPad Prism 5.0 (GraphPad Software, La Jolla,
CA) was used for curve fitting, and SigmaPlot was used for cal-
culation of the half maximal inhibitory concentration (IC50).
Two or three independent experiments with duplicates were
performed for each experiment.
RESULTS
Clinical Features
The clinical features and treatment outcomes of the 13 patients
with NUT carcinoma are summarized in Table 1, and represen-
tative features of NC3 and 13 patients are shown in Figure 1.
Nine cases occurred in the head and/or neck, including the
sinonasal area (n = 7) and salivary gland (n = 2), and four were
of pulmonary origin. The male/female ratio was 1.2:1, and the
median age was 48.0 years (range, 8-73). Initial symptoms
included dyspnea, chest pain, cough, and hemoptysis for pul-
monary NUT carcinoma cases and epistaxis, headache, and
nasal obstruction for the head and/or neck cases, with short
onset times (within 2-4 weeks in most patients). The mean
(SD) main tumor diameter at diagnosis was 5.2 (2.4)
cm. Lymph node involvement and distant metastasis were
observed in six (46%) and three (23%) patients, respec-
tively. The sites of distant metastasis included the bone,
pleura, and adrenal gland. All patients except NC12 and
13 presented with advanced stage (III/IV; stage IV, n = 10)
disease (Table 1).
Table 1. Clinical features and treatment outcomes of patients with NUT carcinoma
No.
Age/
sex Site
Size,
cm
Stage
Initial Sx
Onset,
wk Tx detail
Upfront
CT Rx
Op
extent
CT/RT
response
Tx
failurea Outcome
PFS,
mo
OS,
moT N M TNM
NC1 8/M Maxillary
sinus
5.1 4a 0 0 IVA Nasal
obstruction
2 CT!Op!CCRT!CT FP +
Bleomycin
R2 SD Sys Death 12 16.4
NC2 [20] 12/M Parotid
gland
4.0 3 2b 0 IVA Parotid mass n.a. Op!CCRT IFO R1 PD LR Death 4.6 23.6
NC3 [19] 29/F SMG 1.5 1 2a 1 IVC Neck mass 4 Op!CT!RT DP R0 n.a. None NED 27 27
NC4 [18] 33/F Lung 9.8 4 3 1b IV Chest pain 4 CCRT TC None PR Both Death 5.2 7.9
NC5 [18] 34/M Lung 9.6 3 3 1b IV Dyspnea 2 CT TC None PR Both Death 2.2 3.8
NC6 47/M Nasal
cavity
n.a. 4b 0 0 IVA Headache 4 CCRT!Op!CCRT CDDP R1 PD LR Death 3.8 9.3
NC7 48/F Nasal
cavity
3.5 4a 0 0 IVA Epistaxis 2 Op!CCRT!CT!Op CDDP R2 PR LR Death 7.0 18.7
NC8 51/M Nasal
cavity
5.7 4a 0 0 IVA Epistaxis 20 CT!Op!CCRT DFP R2 PD LR Death 1.5 10.6
NC9 59/F Maxillary
sinus
3.5 4a 2b 0 IVA Maxillary
pain
4 CCRT CDDP None PD Both Death 2.6 3.0
NC10 64/M Nasal
cavity
4.7 4a 0 0 IVA Headache 2 Op!CCRT!CT CDDP R2 PR Sys Death 5.6 8.2
NC11 66/F Nasal
cavity
6.1 3 0 0 III Nasal
obstruction
8 n.a. n.a. n.a. n.a. n.a. AOD n.a. 11.4
NC12 68/M Lung 6.1 2b 1 0 IIB Hemoptysis 3 Op!CT GC R0 n.a. LR AOD 1.4 2.8
NC13 73/F Lung 2.5 2a 0 0 IIA Cough 4 Op!BETi!RT None R0 n.a. LR AOD 4.4 9.7
aTreatment failure type: LR, locoregional; Sys, systemic; Both, locoregional and systemic.
Abbreviations: AOD, alive on disease; BETi, bromodomain and extraterminal inhibitor.; CCRT, concurrent chemoradiotherapy; CDDP, cisplatin; CT, chemotherapy;
DFP, docetaxel, 5-FU, and cisplatin; DP, docetaxel and cisplatin; F, female; FP, 5-FU and cisplatin; GC, gemcitabine and carboplatin; IFO, ifosfamide; M, male; n.a.,
not available; NC, NUT carcinoma; NED, no evidence of disease; No. number of patient; Op, operation; OS, overall survival; PD, progression of disease; PFS,
progression-free survival; PR, partial remission; RT, radiotherapy; Rx, regimen; SD, stable disease; SMG, submandibular gland; Sx, symptom; TC, docetaxel and
cyclophosphamide; Tx, treatment.
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Treatment Outcomes
Therapeutic options were selected at the clinicians’ discretion,
and detailed information was available for 12 patients (Table 1).
Six (50%) patients underwent initial surgery, whereas the other
six received upfront chemotherapy (n = 3) or concurrent
chemoradiotherapy (n = 3); for four patients, surgery was
performed subsequently. The overall response to upfront
chemotherapy or chemoradiotherapy was evaluable in nine
patients, among whom four (44%) had partial responses and
one had stable disease. However, 11 patients experienced
relapse or disease progression, and 9 died of the disease. The
median PFS and OS were 4.4 (range, 1.4-12) and 10.6 (range,
3.0-23.6) months, respectively. Locoregional failure was
observed in nine patients, including three with concomi-
tant systemic failure. By contrast, systemic failure with-
out local recurrence was observed in two patients. Initial
surgery (n = 6) was related to longer OS by the log-rank
test (p = .017). One long-term survivor, NC3, was a 29-year-
old woman with a submandibular gland tumor and distant
metastasis in the para-aortic lymph node (Fig. 1A). She
underwent submandibular gland resection with modified rad-
ical neck dissection plus dissection of the para-aortic lymph
node. Thereafter, she received six cycles of docetaxel plus cis-
platin followed by consolidation radiotherapy and has been
alive without disease for 27 months (Fig. 1B, 1C).
Pathological Findings
Histopathological features are summarized in Table 2, and
representative images are shown in Figure 2. Eight patients
were initially diagnosed with a disease other than NUT car-
cinoma, including poorly differentiated squamous cell carci-
noma (n = 3), sinonasal undifferentiated carcinoma (n = 4),
and mucoepidermoid carcinoma (n = 1). NUT carcinoma
tumors were composed of medium-sized, poorly differenti-
ated cells showing numerous mitoses (Fig. 2A, 2G). Abrupt
keratinization was observed frequently in NC13 (Fig. 2G, 2J)
and NC3. The nuclei of most tumor cells showed NUT
immunostaining, with a speckled pattern in all cases except
NC7, which showed focal NUT expression (Table 2; Fig. 2B,
2H). NUT translocation was confirmed in all cases using
FISH (Fig. 2F, 2O). In NC13, tumor cells harboring three
copies of the NUT gene, including one isolated red signal,
were occasionally observed in addition to a typical split
pattern of the NUT gene (Fig. 2O). Cytokeratin and p63
expression was observed in nine of nine and six of eight
cases, respectively (Fig. 2E, Table 2). p53 and C-MYC
immunostaining was observed in all (12/12) and 67%
(8/12) of evaluated cases, respectively, in a diffuse or
focal pattern (Fig. 2C, 2D, 2L). Of note, the expression
levels of NUT and C-MYC were decreased in keratinized
cells (Fig. 2L). EGFR and HER2 expressions was observed
in 29% (2/7) and 25% (2/8) of evaluable cases, respec-
tively (supplemental online Fig. 1A-C). PD-L1 expression
was observed in only 1 (NC6) of the 12 evaluated cases
whose tissue was obtained after concurrent chemora-
diotherapy (supplemental online Fig. 1D).
In Vitro Sensitivity Study of BET and HDAC Inhibitors
We investigated the effect of targeted inhibitor treatment on
cell proliferation using four cancer cell lines harboring BRD-
NUT gene translocation. Treatement with the monovalent
BET inhibitors, I-BET and OTX-015, and HDAC inhibitors, vori-
nostat and romidepsin, had a moderate or little effect on
NUT carcinoma cell viability. However, treatment with the
HDAC inhibitors, CUDC-907 and panobinostat, and a bivalent
BET inhibitor, AZD5153, resulted in growth inhibition in a
Figure 1. Radiological features of patients NUT carcinoma (NC) 3. (A): An initial positron emission tomography (PET)/computed
tomography (CT) scan showed hypermetabolic lesions located in the left submandibular gland area and para-aortic lymph node
(white arrow). After gross total resection of the primary and metastatic tumors, followed by adjuvant chemotherapy and radio-
therapy, no evidence of remaining tumor was detected in the neck (B) or para-aortic area (C).
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dose-dependent manner (Fig. 3A, 3B), with an IC50 < 10 nmol/L
in the four NUT carcinoma cell lines (supplemental online
Table 1). In particular, CUDC-907 most strongly inhibited the
proliferation of NUT carcinoma cells, including SNU-2972-1
(6.2  0.2 pmol/L), SNU-3178S (5.5  0.2 pmol/L), Ty-82
(7.7  0.2 pmol/L), and HCC2429 (9.0  0.2 pmol/L) cells,
with an IC50 of picomolar range. To understand the mecha-
nism by which CUDC-907 exerts strong cytotoxicity in NUT
carcinoma cells, we performed kinome-wide siRNA library
screening of SNU-3178S and SNU-2972-1 cells. Among
hits, we found that siRNA-mediated knockdown of PIK3CA
resulted in a profound decrease in cell viability in both cell
line models (supplemental online Fig. 2). Given that CUDC-
907 is a potent inhibitor of PI3K as well as HDAC, inhibition
of both molecules may underlie the exquisite sensitivity of
NUT carcinoma cell lines to this compound.
DISCUSSION
Our study demonstrated that the clinicopathological fea-
tures of 13 East Asian patients with NUT carcinoma, most
(83%) of whom had stage IV disease, were similar to those
of Western patients except for the longer median OS of
10.6 months in our series. In addition, local therapy seems
important, as patients who were able to reach surgery had
a better outcome. Kinome siRNA screening revealed PIK3CA
as a shared positive hit; thus, CUDC-907, a dual HDAC and
PI3K inhibitor, was potent against NUT carcinoma cell lines.
Although NUT carcinoma has a dismal outcome (median
OS, 4.7-9.7 months), upfront and intensive local approaches,
such as gross total resection and radiotherapy, may provide
survival benefits (Table 3) [6–8, 10]. Similarly, our six patients
who underwent upfront surgery survived significantly longer
than the others, and two of them with stage IV disease (NC2
and 3) survived for approximately 2 years. Although long-term
remission in response to chemoradiotherapy without surgery
was reported in two patients previously [10, 23], the benefit
of chemotherapy or radiotherapy without surgery was unclear
[8]. In our patients, the long-term survivor, NC3 underwent
aggressive gross total resection, including metastasectomy plus
chemoradiotherapy, which suggests the important role of local
modalities in the treatment of advanced NUT carcinoma.
The head and neck and thorax regions were predilected
sites for NUT carcinoma in our study, as in other studies
(Table 3) [7, 10]. The median age of patients was 48.0 years,
which was older than that reported previously (Table 3)
[6–8, 10]. Because of its rarity and undifferentiated histology,
NUT carcinoma is often misdiagnosed in 61.5% of cases in our
series and 50%-66% of other cases as other tumors, including
undifferentiated and poorly differentiated carcinoma, sinona-
sal undifferentiated carcinoma, and Ewing sarcoma/primary
neuroectodermal tumor [8, 10, 24, 25]. In our archived head
and/or neck carcinoma data set, 40% of tumors initially diag-
nosed as sinonasal undifferentiated carcinoma were subse-
quently diagnosed as NUT carcinoma [24, 25]. NUT carcinoma
is known to be unrelated to oncogenic viruses, such as
Epstein-Barr virus (EBV) and human papillomavirus (HPV),
and tobacco consumption [25]. Therefore, considering the
aggressive behavior of NUT carcinoma, IHC using a highly
specific antibody against NUT should be performed in any
cases of poorly differentiated carcinoma of the head and
neck or lung, particularly in the absence of EBV and HPV. In
addition, molecular assays including FISH for NUT translocation
and reverse transcription polymerase chain reaction for NUT
transcript would be useful for diagnosis [2, 3, 7, 9, 10, 22, 26].
In this study, NC7 showed focal positivity for NUT IHC
despite NUT gene translocation. Because the FFPE block of
Table 2. Pathological findings in patients with NUT carcinoma
No.
Initial
diagnosis
NUT Immunohistochemistry
IHC FISH Keratina p63 NEb p53c C-MYCc EGFR HER2 PD-L1
NC1 SNUD P P P N N P (75%) N N N N
NC2 [20] MEC P P P P N Focal P (30%) N n.a. n.a. N
NC3 [19] NC P P P P N P (85%) P (80%) n.a. P (80%) N
NC4 [18] NC P P n.a. P n.a. P (85%) Focal P (30%) n.a. n.a. N
NC5 [18] NC P P P Focal P N P (80%) Focal P (40%) n.a. n.a. N
NC6 SNUD P P n.a. n.a. n.a. P (50%) Focal P (20%) n.a. n.a. P (10%)
NC7 SNUD Focal P (10%) P P N N P (60%) N N N N
NC8 SqCC P P P P n.a. P (85%) Focal P (10%) P (30%) N N
NC9 SNUD P P P n.a. N P (70%) Focal P (20%) N N N
NC10 NC P P P n.a. N P (70%) P (70%) N N N
NC11 NC P P n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
NC12 SqCC P P P P N P (60%) N N N N
NC13 SqCC P P n.a. n.a. N P (60%) Focal P (30%) P (40%) P (10%) N
aIncluding CK, CK5/6, CK7, CK19, and CK20.
bIncluding chromogranin, CD56, and synaptophysin.
cFor p53 and C-MYC, the results are categorized as negative (0%-10%), focal positive (10%-50%), and positive (>50%).
Abbreviations: EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; MEC, mucoepider-
moid carcinoma; N, negative; n.a., not available; NC, NUT carcinoma; NE, neuroendocrine marker; No. number of patient; P, positive; PD-L1,
programmed cell death ligand 1; SNUD, sinonasal undifferentiated carcinoma; SqCC, squamous cell carcinoma.
© AlphaMed Press 2019
Clinical and Preclinical Findings of NUT Carcinomae744
NC7 was made 7 years previously, protein degradation may
account for the focal positivity of NUT IHC. The NUT gene
translocation pattern was simple in the FISH assay in all cases
except NC13, which showed NUT gene gains with an isolated
red signal in addition to paired green and red signals. Consis-
tently, it was previously reported that chromosomal alter-
ations underlying the simple BRD4/BRD3-NUT transcript can
be highly sophisticated and even harbor hyperdiploidy [18].
In NC13, continuation of the normal bronchial epithelium
and malignant cells was observed where the NUT-positive
cells showed an abrupt transition from NUT-negative cells in
the epithelium (Fig. 2M–N). In a previous report on pulmo-
nary NUT carcinoma [26], tumor cells adjacent to normal
bronchial epithelium showed NUT and thyroid transcription
factor-1 expression, suggesting a bronchial epithelial cell ori-
gin of pulmonary NUT carcinoma. Taken together, these find-
ings suggest that NUT translocation is an initial event of NUT
carcinoma oncogenesis.
IHC features for cytokeratin, p63, and neuroendocrine
markers were comparable to those observed in previous studies
Figure 2. Pathological findings for NUT carcinoma (NC) 3 and NC13. (A): Loose nests of malignant cells show numerous mitotic
figures in NC3. (B–E): Immunohistochemistry of NC3 revealed that the tumor cells were positive for NUT, with a speckled pattern
in the nuclei (insert) (B), and diffusely positive for p53 (C), C-MYC (D), and p63 (E). (F): Translocation of the NUT gene is identified
frequently in break-apart fluorescence in situ hybridization (FISH) in NC3. (G): A sheet of poorly differentiated basaloid cells with
abrupt squamous differentiation foci (arrows) in NC13. (H): Immunohistochemistry of NC13 revealed that the tumor cells were
positive for NUT, with a speckled pattern in the nuclei (insert), and (I) diffusely positive for p53. (J): Foci of squamous differentia-
tion with decreased expression levels of (K) NUT and (L) C-MYC were present in NC13. (M): Tumor cells of NC13 were observed in
the ciliated respiratory epithelium, (N) along with the abrupt transition of NUT expression. (O): A FISH assay demonstrated NUT
break apart and occasional triploidy with an isolated red signal in NC13.
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[9, 24]. We observed high and frequent overexpression of p53
in NUT carcinoma cases. The reason for this finding is uncer-
tain because chromosomal rearrangement or somatic muta-
tion of p53 was not found in the SNU-2972-1 or SNU-317S
cell line in our previous study [18]. p300 HAT is sequestered
to the NUT moiety BRD4-NUT, which, in turn, acetylates p53
and binds it to the BRD4-NUT foci of the chromatin [13]. In
addition, C-MYC is upregulated in NUT carcinoma by BRD4/
BRD3-NUT, and it plays a key role in inhibiting differentia-
tion and promoting the proliferation of NUT carcinoma cells
[11, 14]. C-MYC expression was also observed frequently and
decreased in differentiated cells, consistent with a previous
report [14]. Although a recent study demonstrated that BRD4
promoted PD-L1 expression, and that BET inhibitor enhanced
cytotoxic T cell-dependent antitumor activity by repressing PD-
L1 expression of tumor [27], PD-L1 expression was observed
in only one patient (NC6) who underwent chemoradiotherapy
in our study. Interestingly, EGFR and HER2 expression was
observed in approximately 30% of NUT carcinoma cases, with
no relevance of the differentiation status.
C-MYC-targeting agents, such as BET and HDAC inhibitors,
disperses transcriptionally active chromatin domains and
Figure 3. Cell viability assays for histone deacetylase (HDAC) and bromodomain and extraterminal (BET) inhibitors in NUT carcinoma
(NC) cell lines. Proliferation assays for four NC cell lines treated with increasing doses of HDAC inhibitors (CUDC-907, panobinostat,
vorinostat, and romidepsin) (A) and BET inhibitors (I-BET, OTX-015, and AZD5153) (B) from 0.01 nmol/L to 10,000 nmol/L for 72 h.
Error bars represent the standard deviations of triplicate experiments.
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restores global histone acetylation, respectively, which pro-
mote the differentiation of NUT carcinoma cells and shows
clinical activities [15, 28]. Clinically, OTX015/MK-8628, a novel
BET inhibitor targeting BRD2, BRD3, and BRD4, showed
responses in two of four patients with NUT carcinoma
through compassionate use [17]. AZD5153, which is a biva-
lent BET inhibitor unlike other monovalent BET inhibitors
[29, 30], showed antitumor activity against NUT carcinoma
cell lines, and it is on a phase I clinical trial for patients with
relapsed and/or refractory solid tumors (NCT03205176).
Regarding HDAC inhibitors, vorinostat showed responses in
a short time because of significant adverse events in two
cases [16, 31], whereas romidepsin was not effective in a
21-year-old patient with NUT carcinoma [32]. Considering
that HDAC and PI3K inhibition synergistically reduces the
C-MYC protein level and MYC transcription, CUDC-907, a
dual HDAC/PI3K inhibitor, is potent against MYC-driven
tumors, including the NUT carcinoma xenograft model [33].
These findings are comparable to those of our study, which
demonstrated superior potency against NUT carcinoma cell
lines and positive hit of PIK3CA by kinome siRNA screening.
A phase I study of CUDC-907 (NCT02307240) has involved
the recruitment of patients with advanced and/or relapsed
NUT carcinoma in whom standard therapy failed. However,
because of poor pharmacokinetic properties of hydroxamic
acids that are rapidly cleared and have short half-lives, these
exhibit limited efficacies in patients with solid tumors as
compared with their active in vitro efficacies [34].
CONCLUSION
The clinicopathological findings of East Asian patients with
NUT carcinoma were similar to those of Western patients
with NUT carcinoma and include aggressive behavior, a typ-
ical immunophenotype, and poor survival outcomes, except
for one long-term survivor without evidence of disease
who received aggressive local treatment. A dual HDAC and
PI3K inhibitor showed potent antitumor activity against
in vitro NUT carcinoma models.
ACKNOWLEDGMENTS
This study was supported by a grant from the Korea Health
Technology R&D Project through the Korea Health Industry
Development Institute, funded by the Ministry of Health &
Welfare (Grant HI17C0828, to T.M.K.) and Seoul National
University Invitation Program for Distinguished Scholar (to
Y.K.J.), Republic of Korea.
AUTHOR CONTRIBUTIONS
Conception/design: Tae Min Kim, Yoon Kyung Jeon
Provision of study material or patients: Sun Och Yoon, Heae Surng Park, Soon
Won Hong, Weon-Seo Park, Ji Eun Kim, Hyun Jik Kim, Hyoung Jin Kang
Collection and/or assembly of data: Minsun Jung, Soyeon Kim, June-Koo
Lee, Joon Kim, Kyeong Cheon Jung, Dae Seog Heo, Tae Min Kim, Yoon
Kyung Jeon
Data analysis and interpretation: Minsun Jung, Soyeon Kim, June-Koo Lee,
Bhumsuk Keam, Dong-Wan Kim,Young Tae Kim,TaeMin Kim,Yoon Kyung Jeon
Manuscript writing:Minsun Jung, Soyeon Kim, Tae Min Kim, Yoon Kyung Jeon
Final approval of manuscript: Minsun Jung, Soyeon Kim, June-Koo Lee, Sun
Och Yoon, Heae Surng Park, Soon Won Hong, Weon-Seo Park, Ji Eun Kim,
Joon Kim, Bhumsuk Keam, Hyun Jik Kim, Hyoung Jin Kang, Dong-Wan Kim,
Kyeong Cheon Jung, Young Tae Kim, Dae Seog Heo, Tae Min Kim, Yoon
Kyung Jeon
DISCLOSURES
The authors indicated no financial relationships.
Table 3. Demographic data and treatment outcomes from major NUT carcinoma studies
Demographic data Bauer et al. [7] Chau et al. [8] Lemelle et al. [10] Present study
Demographic findings
Total (n) 63 48 12 13
Male/female 1.1 0.7 0.7 1.2
Median age, yr 16.0 21.9 18.1 48.0
Clinicopathological findings
Primary sites HN = 24, T = 35, other = 4 HN = 48 HN = 3, T = 6, other = 3 HN = 9, T = 4
Stagea n.a. n.a. IV = 9, n.a. = 3 IV = 10, III = 1, II = 2
LN involvement (%) 40 26 75 46
Distant metastasis (%) 51 6 67 23
Treatment modality
Upfront CT (%) n.a. 28 ≥50 25
Upfront surgery (%) n.a. 56 ≤17 50
Radiotherapy (%) ≥49 74 42 42
Survival outcomes
Median OS, mo 6.7 9.7 4.7 10.6
Median PFS, mo NA 6.6 1.9 4.4
abased on AJCC cancer staging manual 7th edition.
Abbreviations: CT, chemotherapy; HN, head/neck; LN, regional lymph node; n.a., not available; OS, overall survival; PFS, progression-free
survival; T, thorax.
© AlphaMed Press 2019www.TheOncologist.com
Jung, Kim, Lee et al. e747
REFERENCES
1. Kubonishi I, Takehara N, Iwata J et al. Novel
t(15;19)(q15;p13) chromosome abnormality in a
thymic carcinoma. Cancer Res 1991;51:3327–3328.
2. French CA, Miyoshi I, Kubonishi I et al.
BRD4-NUT fusion oncogene: A novel mechanism
in aggressive carcinoma. Cancer Res 2003;63:
304–307.
3. French CA, Ramirez CL, Kolmakova J et al.
BRD-NUT oncoproteins: A family of closely related
nuclear proteins that block epithelial differentia-
tion and maintain the growth of carcinoma cells.
Oncogene 2008;27:2237–2242.
4. French CA, Rahman S, Walsh EM et al.
NSD3-NUT fusion oncoprotein in NUT midline
carcinoma: Implications for a novel oncogenic
mechanism. Cancer Discov 2014;4:928–941.
5. Alekseyenko AA, Walsh EM, Zee BM et al.
Ectopic protein interactions within BRD4-chromatin
complexes drive oncogenic megadomain formation
in NUT midline carcinoma. Proc Natl Acad Sci USA
2017;114:E4184–E4192.
6. French CA, Kutok JL, Faquin WC et al. Midline
carcinoma of children and young adults with NUT
rearrangement. J Clin Oncol 2004;22:4135–4139.
7. Bauer DE, Mitchell CM, Strait KM et al. Clinico-
pathologic features and long-term outcomes of
NUT midline carcinoma. Clin Cancer Res 2012;18:
5773–5779.
8. Chau NG, Hurwitz S, Mitchell CM et al.
Intensive treatment and survival outcomes in
NUT midline carcinoma of the head and neck.
Cancer 2016;122:3632–3640.
9. Stelow EB. A review of NUT midline carci-
noma. Head Neck Pathol 2011;5:31–35.
10. Lemelle L, Pierron G, Fréneaux P et al. NUT
carcinoma in children and adults: A multicenter
retrospective study. Pediatr Blood Cancer 2017;
64:e26693.
11. Alekseyenko AA, Walsh EM, Wang X et al.
The oncogenic BRD4-NUT chromatin regulator
drives aberrant transcription within large topo-
logical domains. Genes Dev 2015;29:1507–1523.
12. Filippakopoulos P, Qi J, Picaud S et al. Selec-
tive inhibition of BET bromodomains. Nature 2010;
468:1067–1073.
13. Reynoird N, Schwartz BE, Delvecchio M et al.
Oncogenesis by sequestration of CBP/p300 in tran-
scriptionally inactive hyperacetylated chromatin
domains. EMBO J 2010;29:2943–2952.
14. Grayson AR, Walsh EM, Cameron MJ et al.
MYC, a downstream target of BRD-NUT, is nec-
essary and sufficient for the blockade of differ-
entiation in NUT midline carcinoma. Oncogene
2014;33:1736–1742.
15. Delmore JE, Issa GC, Lemieux ME et al. BET
bromodomain inhibition as a therapeutic strat-
egy to target c-Myc. Cell 2011;146:904–917.
16. Schwartz BE, Hofer MD, Lemieux ME et al.
Differentiation of NUT midline carcinoma by epi-
genomic reprogramming. Cancer Res 2011;71:
2686–2696.
17. Stathis A, Zucca E, Bekradda M et al. Clinical
response of carcinomas harboring the BRD4-NUT
oncoprotein to the targeted bromodomain inhibitor
OTX015/MK-8628. Cancer Discov 2016;6:492–500.
18. Lee JK, Louzada S, An Y et al. Complex chro-
mosomal rearrangements by single catastrophic
pathogenesis in NUT midline carcinoma. Ann
Oncol 2017;28:890–897.
19. Cho Y, Keam BS, Jung KC et al. A case of
nuclear protein in testis midline carcinoma aris-
ing from the submandibular gland duct in a
pregnant patient. J Oral Maxillofac Surg 2017;
75:2020–2024.
20. Park HS, Bae YS, Yoon SO et al. Usefulness
of nuclear protein in testis (NUT) immunohisto-
chemistry in the cytodiagnosis of NUT midline
carcinoma: A brief case report. Korean J Pathol
2014;48:335–338.
21. Eisenhauer EA, Therasse P, Bogaerts J et al.
New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer
2009;45:228–247.
22. Haack H, Johnson LA, Fry CJ et al. Diagnosis
of NUT midline carcinoma using a NUT-specific
monoclonal antibody. Am J Surg Pathol 2009;33:
984–991.
23. Mertens F, Wiebe T, Adlercreutz C et al. Suc-
cessful treatment of a child with t(15;19)-positive
tumor. Pediatr Blood Cancer 2007;49:1015–1017.
24. Bishop JA, Westra WH. NUT midline carci-
nomas of the sinonasal tract. Am J Surg Pathol
2012;36:1216–1221.
25. Stelow EB, Bellizzi AM, Taneja K et al. NUT
rearrangement in undifferentiated carcinomas of
the upper aerodigestive tract. Am J Surg Pathol
2008;32:828–834.
26. Tanaka M, Kato K, Gomi K et al. NUT mid-
line carcinoma: Report of 2 cases suggestive of
pulmonary origin. Am J Surg Pathol 2012;36:
381–388.
27. Zhu H, Bengsch F, Svoronos N et al. BET bro-
modomain inhibition promotes anti-tumor immu-
nity by suppressing PD-L1 expression. Cell Rep
2016;16:2829–2837.
28. French CA. Pathogenesis of NUT midline
carcinoma. Annu Rev Pathol 2012;7:247–265.
29. Rhyasen GW, Hattersley MM, Yao Y et al.
AZD5153: A novel bivalent BET bromodomain inhib-
itor highly active against hematologic malignancies.
Mol Cancer Ther 2016;15:2563–2574.
30. Bradbury RH, Callis R, Carr GR et al. Optimiza-
tion of a series of bivalent triazolopyridazine based
bromodomain and extraterminal inhibitors: The dis-
covery of (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo
[4,3-b]pyridazin-6-yl)-4-piperidyl]phen oxy]ethyl]-1,-
3-dimethyl-piperazin-2-one (AZD5153). J Med Chem
2016;59:7801–7817.
31. Maher OM, Christensen AM, Yedururi S et al.
Histone deacetylase inhibitor for NUT midline carci-
noma. Pediatr Blood Cancer 2015;62:715–717.
32. Maur M, Toss A, Dominici M et al. Impres-
sive response to dose-dense chemotherapy in a
patient with NUT midline carcinoma. Am J Case
Rep 2015;16:424–429.
33. Sun K, Atoyan R, Borek MA et al. Dual HDAC
and PI3K inhibitor CUDC-907 downregulates MYC
and suppresses growth of MYC-dependent can-
cers. Mol Cancer Ther 2017;16:285–299.
34. McClure JJ, Li X, Chou CJ. Advances and
challenges of HDAC inhibitors in cancer thera-
peutics. Adv Cancer Res 2018;138:183–211.
See http://www.TheOncologist.com for supplemental material available online.
© AlphaMed Press 2019
Clinical and Preclinical Findings of NUT Carcinomae748
